We are live on ! Find out more
GDTC icon

CytoMed Therapeutics
GDTC

2 hedge funds and large institutions have $36.1K invested in CytoMed Therapeutics in 2025 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 2 → 2 (0)

0% more first-time investments, than exits

New positions opened: 1 | Existing positions closed: 1

0.36% less ownership

Funds ownership: 0.36% → 0% (-0.36%)

63% less capital invested

Capital invested by funds: $98.5K → $36.1K (-$62.4K)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
2
Holders Change
–
Holders Change %
0%
% of All Funds
0.03%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
–
Reduced
1
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
WANY
Wealthspire Advisors (New York)
New York
+$9.48K

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$58.9K
2
UBS Group
UBS Group
Switzerland
-$8.42K
Name Holding Trade Value Shares
Change 		Change in
Stake
UBS Group
1
UBS Group
Switzerland
$26.4K -$8.42K -4,292 -24%
WANY
2
Wealthspire Advisors (New York)
New York
$9.62K +$9.48K +4,835 New
Citadel Advisors
3
Citadel Advisors
Florida
– -$58.9K -27,669 Closed

GDTC Hedge Fund Activity: Q3 2025 in Review

2 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in CytoMed Therapeutics (GDTC) for Q3 2025, worth a combined $36.1K — down 63% from $98.5K a quarter earlier.

Fund positioning in GDTC was balanced in Q3 2025: 1 fund opened new positions, 1 closed out, 0 added to existing stakes and 1 trimmed.

The largest buyer was Wealthspire Advisors (New York), opening a new position worth an estimated $9.48K. The largest seller was Citadel Advisors, exiting entirely with an estimated $58.9K sold.

  • 2 institutional investors held CytoMed Therapeutics (GDTC) as of Q3 2025, unchanged from Q2 2025.
  • Funds reported $36.1K of CytoMed Therapeutics stock for Q3 2025, down 63% quarter-over-quarter.
  • 1 fund opened new CytoMed Therapeutics positions in Q3 2025 and 1 closed out, a net change of 0 holders.
  • The largest CytoMed Therapeutics buyer in Q3 2025 was Wealthspire Advisors (New York), an estimated $9.48K added.
  • The largest CytoMed Therapeutics seller in Q3 2025 was Citadel Advisors, an estimated $58.9K sold.

Based on aggregated 13F filings for Q3 2025.